Patents by Inventor James A. Flint
James A. Flint has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190112584Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.Type: ApplicationFiled: August 19, 2018Publication date: April 18, 2019Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
-
Publication number: 20170313749Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: ApplicationFiled: July 12, 2017Publication date: November 2, 2017Inventors: Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G.K. Donald, Maninder K. Sidhu, Narender K. Kaylan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
-
Patent number: 9745354Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: GrantFiled: October 31, 2014Date of Patent: August 29, 2017Assignee: Wyeth LLCInventors: Mark E. Ruppen, Justin Keith Moran, Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G. K. Donald, Narender K. Kalyan, Maninder K. Sidhu, Michael James Flint
-
Patent number: 9517060Abstract: A wound closure device including a first tissue anchor with a first suture filament fixedly coupled thereto at a proximal end and extending along a length to a free distal end, and a second tissue anchor with a second suture filament fixedly coupled thereto at a proximal end and extending along a length to a free distal end. The first suture filament is configured to form a slip knot at its proximal end substantially adjacent the first tissue anchor, and the second suture is configured to form a slip knot at its proximal end substantially adjacent the second tissue anchor. The length of the first suture filament passes through the slip knot of the second suture and the length of the second suture filament passes through the slip knot of the first suture filament.Type: GrantFiled: September 27, 2012Date of Patent: December 13, 2016Assignee: Ethicon, Inc.Inventor: James A. Flint
-
Publication number: 20160143637Abstract: A surgical fastener for anchoring medical devices to tissue includes first and second legs lying in a first plane, and third and fourth legs lying in a second plane that is orthogonal with the first plane. A bridge interconnects proximal ends of the four legs for forming a closed end of the surgical fastener. Each leg has a proximal end, a distal end, and an insertion tip with a distal point located at the distal end of the leg. Each leg has an insertion tool alignment guide that extends between the proximal and distal ends of the leg and along a longitudinal axis that is aligned with the distal point of the insertion tip.Type: ApplicationFiled: November 21, 2014Publication date: May 26, 2016Inventors: Robert Nering, Glenn Cook, James A. Flint
-
Publication number: 20160000838Abstract: The present invention relates to medicine, particularly immunology and gastroenterology. Specifically, it relates to probiotic bacteria and extracts thereof for therapeutic use for the treatment of inflammatory disorders such as inflammatory bowel disease. Provided is a composition comprising as active ingredient Faecalibacterium prausnitzii strain HTF-F (DSM 26943) or an extract thereof comprising extracellular polymeric matrix (EPM), and an acceptable carrier, diluent or excipient. Also provided is an anti-inflammatory composition comprising EPM extracted from F. prausnitzii strain HTF-F, and a method for preparing the same.Type: ApplicationFiled: March 5, 2014Publication date: January 7, 2016Applicants: RIJKSUNIVERSITEIT GRONINGEN, THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, WAGENINGEN UNIVERSITEIT, ACADEMISCH ZIEKENHUIS GRONINGENInventors: Hermanus Josef Martinus HARMSEN, Muhammad Tanweer KHAN, Jeremy WELLS, Oriana ROSSI, Harry James FLINT, Sylvia Helen DUNCAN
-
Patent number: 9187536Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: GrantFiled: July 10, 2015Date of Patent: November 17, 2015Assignee: Wyeth LLCInventors: Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
-
Publication number: 20150307563Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: ApplicationFiled: July 10, 2015Publication date: October 29, 2015Inventors: Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
-
Publication number: 20150291940Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.Type: ApplicationFiled: October 7, 2013Publication date: October 15, 2015Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
-
Publication number: 20150125927Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: ApplicationFiled: October 31, 2014Publication date: May 7, 2015Inventors: Mark E. Ruppen, Justin Keith Moran, Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G. K. Donald, Narender K. Kalyan, Maninder K. Sidhu, Michael James Flint
-
Patent number: 8900597Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: GrantFiled: August 19, 2013Date of Patent: December 2, 2014Assignee: Wyeth LLCInventors: Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender Kumar Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
-
Patent number: 8717183Abstract: A leak detector for detecting and locating leaks in a water supply pipe of plastics, the leak detector comprising a first sensor at a first position arranged to detect a leak signal travelling along a pipe, a second sensor arranged to detect a leak signal travelling along the pipe at a second position spaced from the first position, and a processing device adapted to receive the signals from the first sensor and the second sensor. The processing device may be adapted to determine the velocity of the signals from characteristics of the leak signals. The processing device is adapted to use the velocity and distance between the first sensor and the second sensor to determine the location of a leak. The characteristics may be the relationship between the phase and frequency of the leak signals.Type: GrantFiled: September 19, 2011Date of Patent: May 6, 2014Assignee: Severn Trent Water LimitedInventors: Maninder Pal, Neil Dixon, James Flint
-
Publication number: 20140088644Abstract: A wound closure device including a first tissue anchor with a first suture filament fixedly coupled thereto at a proximal end and extending along a length to a free distal end, and a second tissue anchor with a second suture filament fixedly coupled thereto at a proximal end and extending along a length to a free distal end. The first suture filament is configured to form a slip knot at its proximal end substantially adjacent the first tissue anchor, and the second suture is configured to form a slip knot at its proximal end substantially adjacent the second tissue anchor. The length of the first suture filament passes through the slip knot of the second suture and the length of the second suture filament passes through the slip knot of the first suture filament.Type: ApplicationFiled: September 27, 2012Publication date: March 27, 2014Applicant: ETHICON, INC.Inventor: James A. Flint
-
Publication number: 20130330371Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: ApplicationFiled: August 19, 2013Publication date: December 12, 2013Applicant: WYETH LLCInventors: Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender Kumar Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
-
Patent number: 8557548Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: GrantFiled: March 22, 2013Date of Patent: October 15, 2013Assignee: Wyeth LLCInventors: Annaliesa Sybil Anderson, Robert G. K. Donald, Kathrin Ute Jansen, Michael James Flint
-
Publication number: 20130244307Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: ApplicationFiled: March 22, 2013Publication date: September 19, 2013Applicant: WYETH LLCInventors: Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Terri L. Mininni, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
-
Patent number: D768297Type: GrantFiled: October 13, 2014Date of Patent: October 4, 2016Assignee: Ethicon, Inc.Inventors: Robert Nering, Glenn Cook, James A. Flint
-
Patent number: D782674Type: GrantFiled: July 11, 2016Date of Patent: March 28, 2017Assignee: Ethicon, Inc.Inventors: Robert Nering, Glenn Cook, James A. Flint
-
Patent number: RE46376Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: GrantFiled: October 14, 2015Date of Patent: April 25, 2017Assignee: Wyeth LLCInventors: Annaliesa Sybil Anderson, Robert G. K. Donald, Kathrin Ute Jansen, Michael James Flint
-
Patent number: RE46518Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: GrantFiled: December 1, 2016Date of Patent: August 22, 2017Assignee: Wyeth LLCInventors: Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender Kumar Kalyan, Justin Keith Moran, Mark Edward Ruppen, Michael James Flint